GILEAD SCIENCES, INC. - 18 Dec 2024 SCHEDULE 13G/A Report for Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO)

Filing Manager: GILEAD SCIENCES, INC.
Reporting Manager: GILEAD SCIENCES INC
Security: Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share
Symbol: XLO
Shares outstanding: 45,756,035 shares
Disclosed Ownership: 9,105,451 shares
Ownership: 19.9%
Form type: SCHEDULE 13G/A
Filing time: 19 Dec 2024, 16:15:45 UTC
Date of event: 18 Dec 2024
Next filing: 14 Aug 2025
SEC: View on sec.gov

Reporting Managers (1)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
GILEAD SCIENCES INC	19.9%	9,105,451	9,105,451	0	/s/ Andrew D. Dickinson	Executive Vice President and Chief Financial Officer